Law firm Burns & Levinson has expanded its intellectual property practice with the hire of life sciences attorneys John Hamilton and Gabriel Goldman.
The US Court of Appeals for the Federal Circuit has blocked US sales of Sandoz’s Zarxio, the biosimilar version of Amgen’s Neupogen, an injection used to prevent infection in patients undergoing chemotherapy.
The US Court of Appeals for the Federal Circuit has rejected a man’s claim that he was stopped from entering the fitness machine market because he feared infringing patents that were eventually found to be falsely attributed to Nautilus.
The US Supreme Court has rejected pharmaceutical company Bristol-Myers Squibb’s appeal to review a ruling that found its patent covering a treatment for hepatitis B invalid.
Law firm Fish & Richardson has added patent attorney Lisa Chiarini to its intellectual property litigation group.
The English High Court has ruled that a patent covering Novartis’s transdermal patch treatment for Alzheimer’s disease, Exelon, is invalid.
A US court has ruled on how five claims in two patents related to acne drug Absorica should be construed, in a patent infringement case between Canada-based Cipher Pharmaceuticals and Actavis.
The US Court of Appeals for the Federal Circuit has again found a patent covering a heart rate monitor to be valid, reversing and remanding a district court’s decision for further consideration in the long-running Biosig v Nautilus case.
Hedge fund manager Kyle Bass and his Coalition for Affordable Drugs is continuing its campaign against certain pharmaceutical patents, most recently seeking to invalidate patents owned by Celgene and NPS Pharma.
Japanese pharmaceutical company Hisamitsu and its US-based subsidiary Noven have sued Mylan for allegedly infringing two patents covering oestrogen patch Minivelle.